Zacks: Brokerages Expect CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Will Post Earnings of -$0.21 Per Share

Wall Street analysts forecast that CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) will announce ($0.21) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for CNS Pharmaceuticals’ earnings. CNS Pharmaceuticals posted earnings per share of ($0.12) during the same quarter last year, which would indicate a negative year-over-year growth rate of 75%. The company is expected to issue its next quarterly earnings report on Thursday, November 11th.

On average, analysts expect that CNS Pharmaceuticals will report full year earnings of ($0.84) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of ($0.68) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for CNS Pharmaceuticals.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings results on Thursday, August 12th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01.

Several analysts have recently issued reports on the stock. Zacks Investment Research raised shares of CNS Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 1st. Alliance Global Partners started coverage on shares of CNS Pharmaceuticals in a report on Friday, August 27th. They set a “buy” rating and a $4.00 target price on the stock.

CNS Pharmaceuticals stock traded down $0.02 during midday trading on Tuesday, reaching $1.53. 149,528 shares of the stock traded hands, compared to its average volume of 834,884. The firm has a market cap of $42.02 million, a PE ratio of -2.55 and a beta of 2.34. The company has a 50-day simple moving average of $1.68 and a two-hundred day simple moving average of $1.97. CNS Pharmaceuticals has a 12-month low of $1.39 and a 12-month high of $4.46.

Several large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. purchased a new position in CNS Pharmaceuticals in the first quarter valued at approximately $28,000. Jane Street Group LLC purchased a new position in shares of CNS Pharmaceuticals in the 1st quarter valued at $33,000. State Street Corp purchased a new position in shares of CNS Pharmaceuticals in the 2nd quarter valued at $35,000. Commonwealth Equity Services LLC purchased a new stake in CNS Pharmaceuticals in the second quarter valued at $39,000. Finally, Northern Trust Corp purchased a new stake in CNS Pharmaceuticals in the first quarter valued at $77,000. 4.99% of the stock is currently owned by institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.

Further Reading: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on CNS Pharmaceuticals (CNSP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with's FREE daily email newsletter.